Company ProfilePremium

Neurotech International Limited

Company Profile Analysis

Ticker: NTI.AX

ESOMAR 23 Corporate BadgeISO Certifications Badge
Neurotech International Limited - Company showcase

Year Founded & Workforce

2016

Neurotech International Limited logo

Neurotech International Limited Employee Contacts

We don't hold contact details for this company yet — you can request them.

Request Employee Contacts

Neurotech International Limited Overview

Neurotech International is a micro-capitalisation, single-asset, clinical-stage biopharmaceutical company focused on paediatric neurological and neurodevelopmental disorders. Its sole development asset, NTI164, is a proprietary, GMP-grade, multi-constituent oral cannabinoid formulation rich in cannabidiolic acid (CBDA) with select minor cannabinoids and very low THC (0.08% per the Rett publication title), positioned on a neuroinflammation and immune-dysregulation mechanism rather than as a conventional CBD product. After completing a 54-patient Phase II/III study (HARMONY) in Autism Spectrum Disorder (ASD) and open-label Phase I/II studies in Rett syndrome and PANDAS/PANS, the company dosed its first patient in the pivotal Phase 3 "Beyond Harmony" ASD trial in September 2026 across six Australian sites. It holds US FDA IND clearance, US Orphan Drug and Rare Pediatric Disease Designations in Rett syndrome, and an EU orphan designation. Neurotech generates no product revenue, relies on R&D tax incentives and equity, and its value is almost wholly contingent on Phase 3 success and partnering.


Company's own description (FY2026 Annual Report, Principal Activities, paraphrased). Neurotech describes itself as a clinical-stage biopharmaceutical development company concentrated mainly on paediatric neurological disorders, built around a broad-spectrum oral cannabinoid drug therapy, NTI164. It highlights completion of a randomised, double-blind, placebo-controlled Phase II/III trial in ASD with statistically significant and clinically meaningful benefits across several validated measures and a favourable safety profile, completion of Phase I/II studies in ASD, PANDAS/PANS and Rett syndrome, and ethics clearance for a Phase III ASD study. The notes to the accounts additionally describe the group as a biotechnology company conducting clinical studies into the neuroprotective, anti-inflammatory and neuromodulatory activity of its proprietary cannabis strains.

Independent characterisation. Neurotech is best understood as a "virtual" drug developer: it owns intellectual property, regulatory dossiers and clinical data, while outsourcing cultivation/extraction and GMP manufacture (the FY2026 AR cites production across three Australian facilities), clinical operations (hospital sites, CROs), toxicology (GLP studies) and analytics. Its cost base is overwhelmingly clinical: of A$9.05m of FY2026 R&D expense, A$8.43m (93%) was the clinical programme. The company has no sales force, no manufacturing plant and no meaningful revenue.

Business model and revenue model.

Value-chain position. Upstream: proprietary plant genetics (historically described as "NTI/Dolce" strains) and extraction to a standardised CBDA-rich extract, produced by third-party Australian GMP facilities. Midstream: clinical development, regulatory affairs and IP. Downstream (future): either a licensed commercial partner or a self-commercialised specialty paediatric neurology product in Australia, with partner-led commercialisation more likely in the US/EU.

Customer types and end-markets. Prospective customers are paediatric neurologists, developmental paediatricians and psychiatrists treating children with moderate-to-severe (Level 2 and 3) ASD; rare-disease specialists (Rett syndrome); and paediatric immunology/neuropsychiatry clinicians (PANS/PANDAS). Current "customers" are limited to AP-program patients in Australia.

Strategy

Stated strategy (FY2026 AR themes, paraphrased). The Chairman frames FY2026 as the year Neurotech stopped being a generator of early clinical signals and became a company building a registration-grade evidence package. Strategic themes are: (1) execute the registration-enabling Beyond Harmony Phase 3 in ASD as the top priority; (2) pursue a dual TGA and FDA regulatory pathway using Australian pivotal data plus a US PopPK study; (3) broaden NTI164 into Rett syndrome, PANS and cerebral palsy on the anti-inflammatory/neuroprotective mechanism; (4) strengthen the IP estate to 2042; (5) cultivate partnering and licensing interest; (6) use the AP program for patient access and real-world evidence without treating it as a revenue line.

Initiatives in the last 24 months.

Sustainability/ESG commitments. None published beyond the corporate governance statement; the company states it is not subject to significant environmental regulation.

Cost programs. No formal programme announced; the going-concern note reserves the ability to scale back operations if funding is insufficient.

Medium-term financial targets/guidance. No revenue, earnings or margin guidance. The only quantitative guidance is that, upon completion of the August 2026 placement and with existing cash, the company expects to be funded through to topline Phase 3 readout. A topline date has not been published.

Products & Services

The company has a single active product candidate deployed across multiple indications, plus one discontinued device.

NTI164 (lead and only active asset)

AttributeDetail
DescriptionProprietary, multi-constituent, GMP-grade standardised formulation containing CBDA-rich extracts and select minor cannabinoids; full-spectrum plant extract with 0.08% THC per the Rett publication title
Proposed mechanismModulation of neuroinflammatory signalling, immune dysregulation, glial dysregulation and synaptic function; PANS multi-omics showed normalisation of epigenetic, ribosomal and immune pathways after treatment
Formulation / routeOral; PANS study dosing 20 mg/kg/day for 12 weeks
ManufacturingThird-party; production across three Australian facilities (FY2026 AR)
Regulatory statusFDA IND cleared (Jul 2026); FDA Orphan Drug Designation (Rett, late 2024); FDA RPDD (Rett, Oct 2025); EU Orphan Designation (by Apr 2025); Australian AP program active
IPTwo US applications allowed (Jul 2026) — No. 18/698,605 (methods of reducing neuroinflammation) and No. 19/335,945 (methods of treating ASD), both titled "Compositions and Methods for Treating Neurological Disorders"; expected protection to 2042
PricingNo commercial pricing; AP supply priced at cost plus modest margin (amount not disclosed)

Indication-by-indication programme catalogue

ProgrammeIndicationPhase / statusKey data or designTarget patient
Beyond HarmonyASD Levels 2–3Phase 3, first patient dosed 21 Sep 2026; six sites (VIC, QLD, NSW, TAS, WA)Randomised, double-blind, placebo-controlled, adaptive; primary endpoint change from baseline in Vineland-3 Adaptive Behaviour Composite; key secondaries Vineland-3 domains, SRS-2, CGI-I, CGI-S; PI Prof. Michael FaheyChildren with moderate-to-severe ASD
HARMONYASDPhase II/III completed54 patients aged 2–17; statistically significant and clinically meaningful benefits across validated measures; peer-reviewed in Neurotherapeutics (2026)As above
ASD Phase I/IIASDCompletedSafety and efficacy at 28 days, 20 and 32 weeksChildren with ASD
US PopPK studyASDEnabled by FDA IND (Jul 2026); start at company's electionPopulation pharmacokinetic programme to support dose characterisation and US registrationUS paediatric ASD
Rett syndromeRett (MECP2)Phase I/II open-label completed; mechanistic collaboration with University of Sydney (Feb 2026)Published Jul 2025 in Journal of Paediatrics and Child Health: well tolerated, improvements across key symptom areas; FDA ODD + RPDDGirls with Rett syndrome
PANDAS/PANSPaediatric acute-onset neuropsychiatric syndromesPhase I/II open-label completed14-child sub-cohort, 12 weeks: CGI-S improved 4.8→3.3 (p=0.002); significant improvements in anxiety, OCD, tics, ADHD symptoms and quality of life; no serious adverse eventsChildren with chronic relapsing PANS
Spastic cerebral palsyCerebral palsyHREC clearance for Phase I/II (per Sep 2026 "About" statement)Design not disclosedChildren with spastic CP
Authorised Prescriber ProgramRange of neurodevelopmental conditionsActive since Sep 2025Controlled specialist-led access; generates real-world dataAustralian paediatric patients

Mente (discontinued)

AttributeDetail
DescriptionEEG-based home neurofeedback headset and software ("Mente Autism"), marketed as improving engagement and relaxation in autistic children with elevated delta-band activity
LaunchLate 2010s (exact year not disclosed in sources reviewed)
FateSubsidiaries placed into voluntary liquidation due to very small user numbers and no material sales (FY2025/FY2026 AR)

Financial Narrative

Basis. FY2025 and FY2026 figures are taken from the audited FY2026 Annual Report. FY2022–FY2024 net loss and cash figures come from the companies' own Appendix 4E/annual reports (net loss FY2022 A$3,362,241; FY2023 A$7,791,939; FY2024 A$5,069,251; cash FY2022 A$1,895,431; FY2023 A$5,025,795; FY2024 A$11,625,480). Other FY2022–FY2024 line items are from StockAnalysis, Barchart, InvestSMART and Kalkine (agg.). All amounts A$000.

Income statement

Notes: Gross, operating, EBITDA and net margins are not meaningful (revenue is nil or immaterial; aggregator-computed net margins exceed −4,000,000%). Revenue CAGR is not meaningful. D&A was A$289 in FY2025 and nil in FY2026, so EBITDA ≈ operating loss. Weighted average shares: FY2025 1,035,891,510; FY2026 1,182,085,957.

Commentary. The P&L is a function of clinical intensity and the timing of R&D tax refunds. FY2023's step-up in losses reflected HARMONY enrolment; FY2024 was cushioned by a A$3.2m R&D incentive (agg.); FY2025 was the peak burn year (R&D A$9.9m plus A$1.58m non-cash share-based payments mostly tied to Fenix performance rights). FY2026's 38% reduction in net loss was driven not by lower spending (R&D only fell 9%) but by a near-doubling of the R&D refund to A$4.73m (relating to FY2025 expenditure) and a A$968k decline in share-based payments. Because the company recognises R&D grants on a cash-received basis (AR Note 1(f)), reported losses lag the underlying expenditure by roughly one year — a material quirk when comparing periods.

Balance sheet

Notes: Virtually all assets are current. Post balance date (Jul 2026) the company drew a A$3.15m secured loan from Rockford RDF against FY2026/FY2027 R&D refunds — the first debt in the five-year period. FY2026 trade payables jumped to A$2.07m (from A$0.22m), indicating Phase 3 start-up costs accrued but unpaid at year end; this stretch in payables supported reported operating cash flow.

Commentary. Equity has cycled with capital raisings: it peaked at A$11.9m in FY2024 after ~A$11m of financing inflows, then fell to A$0.61m by June 2026, equivalent to net tangible assets of 0.05 cents per share. Accumulated losses of A$58.7m against contributed equity of A$52.5m (plus a A$7.5m share-based payment reserve) show that more than the entire paid-in capital has been consumed.

Cash flow

Sources: FY2026 AR cash flow statement; FY2024 operating and financing flows per InvestSMART/Morningstar (agg., rounded); net change in cash per Barchart and reconciled to reported year-end cash.

Commentary. Gross cash burn (payments to suppliers and employees) was A$11.6m in FY2025 and A$9.0m in FY2026. Quarterly operating outflows in calendar 2026 ran at A$2.2m (Mar-2026 quarter) and A$1.9m (Jun-2026 quarter). With Phase 3 dosing now under way at six sites, burn is likely to rise; management's 4 August 2026 statement that the company is funded to topline rests on its internal budget, which has not been published in detail.

Ratios

Calculated by the analyst from the figures above; FY2022 averages use FY2021 total assets of A$5.006m and equity of ~A$3.862m (Barchart, agg.). ROIC, net debt/EBITDA, interest coverage and cash conversion cycle are not meaningful for a pre-revenue, debt-free (until Jul 2026), loss-making company. The deterioration in the current ratio to 1.29x at June 2026 is the most decision-relevant ratio: it explains the auditor's going-concern emphasis and the July–August 2026 funding actions.

Unlock Company Financials

Unlock this company profile to view its financial data.

View Subscription Plans

Financial Detail

Group Entities

EntityCountryOwnershipFunctionStatus

Neurotech International Limited

Australia

Parent

Holds NTI164 IP, runs clinical/regulatory programme

Active

AAT Research Ltd

Malta

100% (direct)

Parent of AAT Medical

Being wound up (voluntary liquidation decision, Jun-2025 quarter) — still consolidated at 30 Jun 2026

AAT Medical Ltd

Malta

100% (indirect)

Mente device research and development

Being wound up — still consolidated at 30 Jun 2026

Revenue by Segment and Revenue by Segment (%)

MetricFY2024FY2025FY2026

Segment operating revenue (AUD K)

00.20

R&D tax incentive income (AUD K)

3,1802,4444,734

Segment R&D expense (AUD K)

5,2509,9429,047

Segment pre-tax loss (AUD K)

-5,069-10,599-6,539

Share of group revenue (%)

100100100

Segment Revenue

CategoryFY2025FY2026

Product development and formulation

395321

Clinical programme

9,2838,433

Patent and IP

264172

Other R&D

0122

Total R&D expense

9,9429,047

Income Statement and Per-Share Data

MetricFY2022FY2023FY2024FY2025FY2026

Operating revenue (AUD K)

401000.20

R&D tax incentive / grant income (AUD K)

5701,1903,1802,4444,734

Interest income (AUD K)

06016013745

Total revenue and other income (AUD K)

6101,2603,3402,5814,807

Gross profit (AUD K)

401000.20

R&D expense (AUD K)

2,5806,4505,2509,9429,047

Share-based payments expense (AUD K)

———1,580612

Employee benefits expense (AUD K)

———795678

Operating income ex-interest (AUD K)

-3,360-7,850-5,230-10,736-6,584

EBITDA (AUD K)

-3,360-7,850-5,229-10,736-6,584

Pre-tax income (AUD K)

-3,362-7,792-5,069-10,599-6,539

Net income (AUD K)

-3,362-7,792-5,069-10,599-6,539

EPS basic (A$ cents)

———-1.02-0.55

EPS diluted (A$ cents)

———-1.02-0.55

Dividends per share (A$ cents)

00000

Balance Sheet

MetricFY2022FY2023FY2024FY2025FY2026

Total assets (AUD K)

2,0235,30912,2133,2402,747

Cash and equivalents (AUD K)

1,8955,02611,6253,0312,386

Short-term debt (AUD K)

00000

Long-term debt (AUD K)

00000

Net debt (AUD K)

-1,895-5,026-11,625-3,031-2,386

Total liabilities (AUD K)

5931,3473152862,136

Total equity (AUD K)

1,4303,96211,8992,955611

Goodwill and intangibles (AUD K)

00000

Working capital (AUD K)

1,4303,96211,8982,955611

Accumulated losses (AUD K)

——-41,557-52,156-58,695

Contributed equity (AUD K)

——46,73548,91452,494

Cash Flow

MetricFY2022FY2023FY2024FY2025FY2026

Operating cash flow (AUD K)

——-4,600-9,024-4,224

Of which R&D tax refund received (AUD K)

———2,4444,734

Capex (AUD K)

-30000

Free cash flow (AUD K)

——-4,600-9,024-4,224

Net financing cash flow (AUD K)

——11,2004303,580

Dividends paid (AUD K)

00000

Share buybacks (AUD K)

00000

Net change in cash (AUD K)

-2,9323,1306,600-8,595-645

Returns & Leverage Ratios (%) and Financial Ratios (x)

RatioFY2022FY2023FY2024FY2025FY2026

ROE (% on average equity)

-127-289-64-143-367

ROA (% on average assets)

-96-213-58-137-218

Current ratio (x)

3.413.9438.7711.331.29

Debt to equity (x)

00000

Asset turnover (x)

0.010000

Revenue by Region

RegionFY2024FY2025FY2026

Australia operating revenue (AUD K)

00.20

Malta / Europe operating revenue (AUD K)

000

Americas operating revenue (AUD K)

000

Total operating revenue (AUD K)

00.20

Share Price

MetricFY2021FY2022FY2023FY2024FY2025

Share price at 30 June (AUD)

0.0530.070.040.070.015

Share Price & Returns

Period (to late Aug 2026, approx. A$0.013)Return (%)

1 year (from A$0.015, Jun 2025)

-13

3 years (from A$0.04, Jun 2023)

-68

5 years (from A$0.053, Jun 2021)

-75

Capital Markets

MeasureValueComment

Market cap

~A$21m

~1.62bn shares × A$0.013

Enterprise value

~A$15–19m (indicative)

Market cap less pro-forma cash (A$2.4m at 30 Jun plus ~A$4.2m net placement and A$3.15m loan proceeds, less loan)

P/E

n/m

Loss-making

EV/EBITDA

n/m

Negative EBITDA

EV/Sales

n/m

No sales

P/B

~34x on 30 Jun 2026 book (A$0.61m)

Book value depressed; pro-forma book after August raise is higher

Capital Markets — Analyst consensus

ItemStatus

Analyst consensus

None identified; no published broker coverage found

Dividend history and policy

No dividends ever paid; none expected

Credit ratings (Moody's/S&P/Fitch)

Not rated

Capital structure overhang

40m management options (strike A$0.10–0.18, out of the money); 19.5m adviser options (A$0.02–0.03); 22.5m proposed JLM options (A$0.02/0.035); up to 35m Fenix performance rights

Index membership

Not in S&P/ASX indices; no ETF holders

Analyst Conclusions

Management guidance. The company guides only that it expects the August 2026 placement plus existing cash to fund operations to topline Phase 3 data; no timing for topline, revenue or earnings guidance has been given. Consensus growth expectations: none (no coverage).

Bull case

  1. HARMONY's statistically significant, peer-reviewed results across multiple validated scales, combined with a pivotal Phase 3 now dosing at six sites with strong recruitment demand, provide a credible path to the first approved therapy for ASD core symptoms.

  2. Regulatory scaffolding is unusually well developed for a ~A$21m company: FDA IND, ODD and RPDD in Rett, EU orphan designation, clean GLP toxicology and US method patents to 2042 — assets that would be valued by a licensee.

  3. The share register is priced for failure; a positive interim or topline readout, or a licence deal, would trigger re-rating mechanics already embedded in management and Fenix incentives (A$200–300m market cap hurdles, A$0.25–0.30 VWAP hurdles).

Bear case

  1. ASD core-symptom trials have a poor industry record; a 54-patient Phase II/III result is a fragile foundation, and the change in planned enrolment from 150 to up to 200 hints at uncertainty about effect size.

  2. The balance sheet is precarious: A$0.61m of net assets at June 2026, an audit going-concern emphasis and rising Phase 3 burn mean the "funded to topline" claim leaves little margin; further raises near A$0.014 would continue heavy dilution.

  3. FDA may not accept Australian-only pivotal efficacy data or botanical manufacturing consistency without additional US studies, delaying the US value inflection on which a licensing deal would rest.

Key catalysts and monitorables (next 12 months)

Analyst verdict. Neurotech International is a binary, single-asset bet on whether a CBDA-rich, multi-cannabinoid extract can do what no approved drug does: measurably improve adaptive behaviour in children with moderate-to-severe autism. FY2026 marked a genuine transition. The company converted a decade of meandering — from a Maltese neurofeedback headset to cannabis strains to a cluster of small open-label studies — into a disciplined, registration-oriented programme with an FDA-cleared IND, orphan and rare-paediatric designations in Rett, GLP toxicology supporting chronic dosing, a peer-reviewed placebo-controlled dataset and, since 21 September 2026, a pivotal Phase 3 dosing across six Australian sites. Those are real assets, and at roughly A$21 million of market value the market is ascribing little to them.

The discount, however, is earned. The company ended FY2026 with A$2.4 million of cash, A$0.6 million of net assets, payables that had swollen nine-fold as Phase 3 costs accrued, and an auditor-flagged material uncertainty over going concern. Survival has relied on equity issued at 1.4 cents and on borrowing against future tax refunds; share count has risen by more than half in fourteen months. The board is small, now led by an executive chairman whose background is capital raising, and lacks the committee architecture that institutional investors expect. The scientific risk is material too: autism trials frequently fail, HARMONY enrolled only 54 children, and the planned Phase 3 size has already moved.

Our view: the investment case is a call option on Beyond Harmony topline data and on the company's ability to convert its regulatory package into a licensing transaction before the next funding gap. Appropriate monitorables are quarterly burn versus the "funded to topline" guidance, enrolment velocity, any adaptive-interim disclosures and the terms of any partnership. Position sizing should assume a meaningful probability of further dilution and a non-trivial probability of total loss, balanced against multi-bagger upside on clean Phase 3 success. Rating stance: speculative; suitable only for high-risk, event-driven biotech allocations.

Unlock Company Financials

Unlock this company profile to view its financial data.

View Subscription Plans

Executive Leadership

Board of Directors

NameTitleTenureBackgroundEducationInterests (FY2026 AR)

Mark Davies

Executive Chairman (from 17 Aug 2026); Non-Executive Chairman 15 Aug 2022–16 Aug 2026; service agreement from 27 May 2019

Board since 2019

20+ years in trading, investment banking and corporate advice; Montagu Stockbrokers; co-founder of Cygnet Capital and later 1861 Capital; former Non-Executive Chairman of Tryptamine Therapeutics (ASX: TYP)

B.Com, University of Western Australia

18,935,875 shares

Dr Anthony Filippis

Managing Director and CEO

Since 1 Feb 2025

25+ years across biotech, healthcare and investment; neuroscience, oncology and endocrinology; senior roles at ASX-listed and private life-science companies; licensing and M&A experience; NED of VivaZome Therapeutics and Connectivity Limited

PhD Biochemistry; MBA

3,571,428 shares; 20m options ($0.16/$0.18, expiring 24 Feb 2030)

Robert (Max) Johnston

Non-Executive Director

Since 19 Apr 2024

11 years as President and CEO of Johnson & Johnson Pacific; senior roles at Unilever and Guinness-United Distillers; past President of ACCORD Australasia, Vice Chair of AFGC, ASMI board; NED of Inoviq (ASX: IIQ)

—

4,604,761 shares

Gerald Quigley

Non-Executive Director and Director of Public Relations

Since 7 Jul 2022

Pharmacist and national media health commentator; experience in pharmaceutical/nutraceutical development and TGA/FDA positioning

B.Pharm

3,849,205 shares

Alessandra Gauvin

Company Secretary

—

8+ years company secretarial experience with ASX-listed companies

B.Com (Accounting and Business Law); Grad. Dip. Applied Corporate Governance; Chartered Secretary

—

Prof. Michael Fahey

Principal Investigator, Beyond Harmony; manages AP program

Long-standing

Paediatric neurologist, Monash

—

Not a KMP

“—” = not publicly disclosed.

Directors' Remuneration

KMPSalary/feesSuperannuationAnnual leaveOptions (SBP)TotalPerformance-related %

Mark Davies

100,000000100,0000

Robert Johnston

50,00000050,0000

Gerald Quigley

50,00000050,0000

Anthony Filippis

420,00050,40014,016128,883613,29921

Total

620,00050,40014,016128,883813,299—

Board & Management Changes

DateChangeContext

26 Jul 2024

Dr Alexandra Andrews ceases employment (received A$60,000 termination benefit)

Management restructuring

1 Feb 2025

Dr Anthony Filippis appointed MD/CEO

Shift toward late-stage development and partnering

1 Apr 2025

Thomas Duthy (Executive Director) resigns

Board streamlining

17 Aug 2026

Mark Davies becomes Executive Chairman

Focus on funding, partnering/licensing and capital markets during Phase 3

Major Shareholders

Holder (top 10 not fully disclosed)Shares%

The Trust Company (Australia) Limited <MOF A/C>

30,506,5002.91

Mark Davies (director, indirect)

18,935,8751.17

Robert Johnston (director)

4,604,7610.28

Gerald Quigley (director)

3,849,2050.24

Anthony Filippis (director)

3,571,4280.22

Competitive Landscape

Key Competitors

CompanyArea of overlapAssetStatusRelative positioning vs NTI

Jazz Pharmaceuticals (Nasdaq: JAZZ)

Cannabinoid neurology

Epidiolex (purified CBD)

Approved for Dravet, Lennox-Gastaut, TSC seizures; ~US$0.9–1.0bn annual sales (approx.)

Validates cannabinoid medicines; prescribers may use off-label in ASD; massive scale advantage

Acadia Pharmaceuticals (Nasdaq: ACAD)

Rett syndrome

Daybue (trofinetide)

FDA-approved 2023; several hundred US$m annual sales (approx.)

Incumbent Rett standard; NTI would need differentiated tolerability (Daybue has GI side-effects)

Neuren Pharmaceuticals (ASX: NEU)

Rett, neurodevelopmental

Trofinetide royalties; NNZ-2591

Royalty-funded; Phase 2/3 programmes

ASX peer in paediatric neurodevelopment; far larger market cap

Harmony Biosciences (Nasdaq: HRMY) via Zynerba

Cannabinoid, neurodevelopmental

Zygel (transdermal CBD) for Fragile X / ASD-adjacent

Late-stage (status should be checked)

Direct cannabinoid-in-neurodevelopment comparator with big-company backing

Otsuka / BMS (aripiprazole); J&J (risperidone)

ASD irritability

Atypical antipsychotics

Approved for irritability, not core symptoms

Standard of care NTI aims to complement or displace on tolerability

Roche

ASD core symptoms

Balovaptan

Discontinued after Phase 3

Illustrates high failure rate in ASD core-symptom trials

Curemark

ASD

CM-AT (enzyme)

Late-stage/regulatory (status uncertain)

Alternative non-psychotropic approach

Axial Therapeutics

ASD (gut-brain)

AB-2004

Clinical stage

Mechanistic competitor in ASD irritability

Bod Science / Zelira Therapeutics / Incannex (ASX/Nasdaq)

Medicinal cannabis R&D

Various cannabinoid formulations

Clinical/early commercial

Compete for investor capital and clinician mind-share in Australian cannabinoid medicine

Australian medicinal cannabis suppliers (prescribed under SAS/AP)

Unregistered cannabinoid products

CBD oils

Widely prescribed

Low-cost "grey" competition; NTI's registration would be a differentiator

Peer Comparison FY2026

MetricNeurotech (FY2026)Neuren (approx.)Acadia (approx.)Jazz (approx.)

Revenue

~A$0

Royalty/milestone income in the A$ tens to hundreds of millions

Hundreds of US$m (total company ~US$1bn)

~US$4bn total company

Revenue growth

n/m

Volatile (milestones)

Positive

Low single digit

Profitability

Net loss A$6.5m

Profitable in milestone years

Near break-even/profitable

Profitable

R&D intensity

~79% of expenses

High

~20–30% of revenue

~20% of revenue

Recent Developments

Litigation, regulatory enforcement, layoffs or guidance revisions: none identified.

Company Snapshot

2016

Founded

Melbourne, Australia

Headquarters

SWOT Analysis

Strengths

  • Randomised, double-blind, placebo-controlled Phase II/III ASD data (HARMONY, n=54) reported as statistically significant across multiple validated measures and published in Neurotherapeutics (2026).
  • Phase 3 under way: six Australian sites initiated and first patient dosed on 21 Sep 2026.
  • FDA IND cleared (14 Jul 2026), enabling a US PopPK programme to complement Australian pivotal data.
  • Layered US regulatory incentives in Rett: Orphan Drug Designation (late 2024) and Rare Pediatric Disease Designation (Oct 2025); EU orphan designation (by Apr 2025).
  • Favourable non-clinical safety: no dose-limiting toxicities in a 90-day GLP Beagle study at up to 216 mg/kg/day (~10x the highest human dose studied) (Feb 2026).
  • Lean structure and high R&D concentration: clinical programme spend of A$8.43m was 93% of FY2026 R&D; KMP pay totalled only A$0.81m.
  • Strong patient demand: more than 200 referred patients (Jun-2026 quarter) and 300+ enquiries (Sep 2026).

Weaknesses

  • Single-asset dependence: the annual report states the company is substantially dependent on NTI164.
  • Thin balance sheet: net assets A$0.61m and cash A$2.39m at 30 Jun 2026; current ratio 1.29x.
  • Going-concern material uncertainty highlighted by BDO in the FY2026 audit report.
  • No revenue (FY2026 nil operating revenue) and AP program designed to be cost-neutral.
  • Failed prior commercial venture (Mente) with negligible sales led to liquidation of subsidiaries.
  • Governance limitations: four-person board, executive chair since Aug 2026, no standalone audit or remuneration committees.
  • Small prior study sizes (14-child PANS sub-cohort; open-label Rett and PANS studies).

Opportunities

  • First-in-class approval for ASD core symptoms, where the company stresses no established medication exists.
  • Licensing deal(s) for US/EU — explicitly a priority of the Executive Chairman and tied to CEO and Fenix incentives.
  • Rett syndrome orphan pathway with potential exclusivity and priority-review economics.
  • Indication expansion into PANS/PANDAS and spastic cerebral palsy (HREC clearance for Phase I/II).
  • US patent issuance from the July 2026 Notices of Allowance, extending protection to 2042.
  • Continued non-dilutive funding via R&D refunds (A$4.73m in FY2026; ~A$3.5m expected per Mar-2026 quarter commentary) and refund-backed loans.

Threats

  • High historical failure rate of ASD core-symptom Phase 3 trials (e.g., Roche balovaptan discontinuation).
  • FDA acceptance risk for Australian-only pivotal data and botanical CMC consistency.
  • Further dilution: shares on issue rose from 1.05bn (Jun 2025) to 1.62bn (Aug 2026), a ~54% increase in 14 months, with all raises at A$0.014.
  • Competition from approved therapies (Daybue in Rett; antipsychotics for irritability) and unregistered cannabinoid oils.
  • Policy change: NDIS reforms and evolving cannabinoid regulation in Australia.
  • Execution risk at small scale: recruitment, retention and supply across six sites with a lean team.

Unlock Company Financials

Unlock this company profile to view its financial data.

View Subscription Plans

Key Developments

DateEventSignificance
1 Apr 2025Executive Director Thomas Duthy resignsBoard reduced to four
2 Apr 2025EU Orphan Designation triggers Fenix Class B vestingRegulatory validation in EU
Jul 2025Mente subsidiaries to be placed into voluntary liquidation (Jun-2025 quarterly)Exit from devices
Jul 2025Rett Phase I/II results published (J. Paediatrics and Child Health)Peer-reviewed support for Rett path
29 Aug 2025FY2025 Annual Report: loss A$10.6m; net assets fell to A$2.95mFunding pressure evident
Sep 2025Authorised Prescriber Program launchedPatient access, real-world data
Oct 2025FDA Rare Pediatric Disease Designation (Rett)Second US designation
Nov 2025A$4.73m R&D tax refund receivedNon-dilutive funding
14–16 Dec 2025Trading halt; ~A$4m placement commitments (final ~A$3.75m at A$0.014)Dilutive funding
Jan 2026PANS data published in NeurotherapeuticsMechanistic credibility
2 Feb 2026HREC approval for Beyond Harmony Phase 3Gate to pivotal study
Feb 2026Positive 90-day GLP Beagle toxicology studySupports chronic dosing, IND
18 Feb 2026University of Sydney Rett collaborationMechanism work
26 Feb 2026Half-year result: loss A$0.70m; cash A$6.34m at 31 Dec 2025Refund-aided H1
17 Mar 2026First Phase 3 site (Monash Children's) activated; 150 patients plannedPivotal trial opens
18–23 Mar 2026Corporate presentation; NWR Virtual Healthcare ConferenceInvestor outreach
30 Mar 2026Director placement shares issued (~A$250k) after GM approvalInsider alignment
Apr 2026CEO presents at Ignite Investment Summit, Hong KongAsian investor outreach
24–28 Apr 2026Johnston options expire; cessation of securities noticesHousekeeping
29 Apr 2026Mar-2026 quarter: cash ~A$4.3m, outflows ~A$2.2m; ~A$3.5m R&D refund expectedRunway watch
May 2026Australian Microcap Investment Conference; NTI Advocacy DayCommunity engagement
Jun 2026Gold Coast Investment ShowcaseInvestor outreach
2 Jul 2026USPTO Notices of Allowance (two US applications)IP to 2042
14 Jul 2026FDA clears IND for NTI164US pathway established
15 Jul 2026A$3.15m Rockford R&D loanBridging liquidity
31 Jul 2026Jun-2026 quarter: cash ~A$2.4m; outflows ~A$1.9m; 200+ patients referredRecruitment demand
4 Aug 2026~A$4.5m placement at A$0.014; funded to topline per companyPhase 3 funded (per company)
17 Aug 2026Mark Davies appointed Executive ChairmanGovernance change
26 Aug 2026FY2026 Annual Report and Appendix 4ELoss A$6.54m; going-concern uncertainty
16 Sep 2026Director-nomination deadline for AGMAGM on or after 4 Nov 2026
Sep 2026 (expected)GM to approve Tranche 2 placement and JLM options–
21 Sep 2026All six sites initiated; first patient dosed; up to 200 patients; 300+ caregiver enquiriesPivotal trial under way

Financial Performance

Explore key financial metrics, segmented revenue, balance sheet health, and performance trends.

Revenue

4 charts
Income Statement: Revenue & Gross Profit: Total revenue and other income rose from AUD 0.6 Mn in FY2022 to AUD 4.8 Mn in FY2026.
Neurotech International Limited — Income Statement: Revenue & Gross Profit
Series (AUD Mn)FY2022FY2023FY2024FY2025FY2026
Total revenue and other income0.61.33.32.64.8
Operating revenue00000
Gross profit00000

Unlock Company Financials

Unlock this company profile to view its financial data.

View Subscription Plans

Unlock Company Contacts

Connect with Key Decision-Makers

Access verified employee contacts and decision-maker information from this company to support your sales, lead generation, and business development efforts.